Graff JN - Search Results

1

Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysis.

Newby TA, Graff JN, Ganzini LK, McDonagh MS. Newby TA, et al. Among authors: graff jn. Psychooncology. 2015 Dec;24(12):1686-93. doi: 10.1002/pon.3781. Epub 2015 Mar 5. Psychooncology. 2015. PMID: 25753507 Review.

2

Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.

Graff JN, Gordon MJ, Beer TM. Graff JN, et al. Expert Opin Pharmacother. 2015 Apr;16(5):749-54. doi: 10.1517/14656566.2015.1016911. Epub 2015 Feb 17. Expert Opin Pharmacother. 2015. PMID: 25687355 Review.

3

Should docetaxel be administered earlier in prostate cancer therapy?

Graff JN, Beer TM. Graff JN, et al. Expert Rev Anticancer Ther. 2015;15(9):977-9. doi: 10.1586/14737140.2015.1074042. Epub 2015 Jul 29. Expert Rev Anticancer Ther. 2015. PMID: 26223224

4

Metastatic prostate cancer in 2015: The new and the old that is new again.

Graff JN, Beer TM. Graff JN, et al. Nat Rev Clin Oncol. 2016 Feb;13(2):73-4. doi: 10.1038/nrclinonc.2015.226. Epub 2015 Dec 31. Nat Rev Clin Oncol. 2016. PMID: 26718107 No abstract available.

5

Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?

Graff JN, Alumkal JJ, Beer TM. Graff JN, et al. JAMA Oncol. 2017 Jan 1;3(1):11-12. doi: 10.1001/jamaoncol.2016.3623. JAMA Oncol. 2017. PMID: 27812686 No abstract available.

6

Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer.

Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Podolak J, et al. Among authors: graff jn. Oncotarget. 2017 Mar 13;8(42):71447-71455. doi: 10.18632/oncotarget.16169. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069718 Free PMC article.

7

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Saad F, et al. Among authors: graff jn. Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10. Lancet Oncol. 2018. PMID: 30213449 Clinical Trial.

8

Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.

Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM. Graff JN, et al. Front Oncol. 2020 Aug 7;10:1381. doi: 10.3389/fonc.2020.01381. eCollection 2020. Front Oncol. 2020. PMID: 32850444 Free PMC article.

9

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study.

Graff JN, Mori M, Li H, Garzotto M, Penson D, Potosky AL, Beer TM. Graff JN, et al. J Urol. 2007 Apr;177(4):1307-12. doi: 10.1016/j.juro.2006.11.054. J Urol. 2007. PMID: 17382720 Clinical Trial.

10

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results.

Prins RC, Rademacher BL, Mongoue-Tchokote S, Alumkal JJ, Graff JN, Eilers KM, Beer TM. Prins RC, et al. Among authors: graff jn. Urol Oncol. 2012 Jan-Feb;30(1):33-7. doi: 10.1016/j.urolonc.2009.11.012. Epub 2010 Mar 6. Urol Oncol. 2012. PMID: 20207556 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters